Core Team
Thomas Stackhouse
Thomas M. Stackhouse, Ph.D.
Associate Director for the Technology Transfer Center (TTC) at the National Cancer Institute (NCI)
Dr. Stackhouse is the Associate Director for the Technology Transfer Center (TTC) at the National Cancer Institute, NIH. In this position, Dr. Stackhouse oversees the patent portfolio and marketing activities for the National Cancer Institute, including its Frederick Maryland campus and the newly formed Frederick National Laboratory for Cancer Research (FNL)
In addition, Dr. Stackhouse leads the TTC staff by coordinating intellectual property parameters and guidelines for several key NCI initiatives including NCI’s Alliance for Nanotechnology in Cancer and the NCI Chemical Biology Consortium. Dr. Stackhouse works closely with state and local economic development groups to foster new partnerships which facilitate the use of NCI technologies and expertise to advance the pubic health and stimulate the nation’s economies. Dr. Stackhouse is Vice Chair of the Education and Training Committee of the Federal Laboratory Consortium (FLC) and an elected member the Executive Board of the FLC
Prior to joining the NCI-Technology Transfer staff in 1996, Dr. Stackhouse received his Ph.D. in Biochemistry from the University of California, Davis. Dr. Stackhouse spent several years as a Developmental Scientist for a major pharmaceutical company and later was part of the research team who discovered the VHL tumor suppressor gene. Dr. Stackhouse has received several awards including the National Institutes of Health Award of Merit for his outstanding management of the NCI-Frederick Technology Transfer Office and the FLC Mid-Atlantic Technology Transfer Representative of the Year
Associate Director for the Technology Transfer Center (TTC) at the National Cancer Institute (NCI)
Dr. Stackhouse is the Associate Director for the Technology Transfer Center (TTC) at the National Cancer Institute, NIH. In this position, Dr. Stackhouse oversees the patent portfolio and marketing activities for the National Cancer Institute, including its Frederick Maryland campus and the newly formed Frederick National Laboratory for Cancer Research (FNL)
In addition, Dr. Stackhouse leads the TTC staff by coordinating intellectual property parameters and guidelines for several key NCI initiatives including NCI’s Alliance for Nanotechnology in Cancer and the NCI Chemical Biology Consortium. Dr. Stackhouse works closely with state and local economic development groups to foster new partnerships which facilitate the use of NCI technologies and expertise to advance the pubic health and stimulate the nation’s economies. Dr. Stackhouse is Vice Chair of the Education and Training Committee of the Federal Laboratory Consortium (FLC) and an elected member the Executive Board of the FLC
Prior to joining the NCI-Technology Transfer staff in 1996, Dr. Stackhouse received his Ph.D. in Biochemistry from the University of California, Davis. Dr. Stackhouse spent several years as a Developmental Scientist for a major pharmaceutical company and later was part of the research team who discovered the VHL tumor suppressor gene. Dr. Stackhouse has received several awards including the National Institutes of Health Award of Merit for his outstanding management of the NCI-Frederick Technology Transfer Office and the FLC Mid-Atlantic Technology Transfer Representative of the Year
Rosemarie Truman
Rosemarie Truman
Founder, The Center for Advancing Innovation, INC.
Rosemarie has over 20 years of experience in driving growth for clients, having created over $21 billion in new profits for clients that launched over 100 new products/services/solutions. Her experience spans strategy consulting, investment banking, and entrepreneurship. Rosemarie has provided strategy consulting services for over 110 clients in over 15 countries and 24 states. Having started her career at Goldman Sachs as an analyst, to this day, Rosemarie's core competencies are in complex due diligence and portfolio strategy, creating sustainable growth breakthrough strategies for clients and transformation
Currently, Ms. Truman is founder and CEO of a global public-private partnership whose mission is to accelerate and increase the volume of technology transfer, translational research and commercialization. Her firm, The Center for Advancing Innovation, has been working with the Avon Foundation on Portfolio Strategy and also has Partnership Intermediary agreements with the National Institutes of Health, National Cancer Institute, the National Heart, Lung and Blood Institute and six other research institutes within the NIH. With the NIH, CDC, and the Heritage provider network, her firm is serving as managing director of a first-of-a-kind national business plan and startup Challenge for select brain focused inventions
Prior to launching her own firm, Rosemarie served as the global leader of IBM and PRTM's Innovation and R&D strategy practice; the VP and head of global strategy at Marsh & McLennan; leader in Oracle's Advanced Technology Group and also led eBusiness Strategy while at Ernst & Young. At IBM, Rosemarie also led internal transformation efforts in the Emerging Business Opportunity area to create models that drive sustainable "growth breakthroughs." Finally, Rosemarie has spearheaded the development of several trade secret models, frameworks and to select and nurture sustainable growth opportunities; one model is for the Life Sciences industry called "Industry Leading R&D Performance"
Founder, The Center for Advancing Innovation, INC.
Rosemarie has over 20 years of experience in driving growth for clients, having created over $21 billion in new profits for clients that launched over 100 new products/services/solutions. Her experience spans strategy consulting, investment banking, and entrepreneurship. Rosemarie has provided strategy consulting services for over 110 clients in over 15 countries and 24 states. Having started her career at Goldman Sachs as an analyst, to this day, Rosemarie's core competencies are in complex due diligence and portfolio strategy, creating sustainable growth breakthrough strategies for clients and transformation
Currently, Ms. Truman is founder and CEO of a global public-private partnership whose mission is to accelerate and increase the volume of technology transfer, translational research and commercialization. Her firm, The Center for Advancing Innovation, has been working with the Avon Foundation on Portfolio Strategy and also has Partnership Intermediary agreements with the National Institutes of Health, National Cancer Institute, the National Heart, Lung and Blood Institute and six other research institutes within the NIH. With the NIH, CDC, and the Heritage provider network, her firm is serving as managing director of a first-of-a-kind national business plan and startup Challenge for select brain focused inventions
Prior to launching her own firm, Rosemarie served as the global leader of IBM and PRTM's Innovation and R&D strategy practice; the VP and head of global strategy at Marsh & McLennan; leader in Oracle's Advanced Technology Group and also led eBusiness Strategy while at Ernst & Young. At IBM, Rosemarie also led internal transformation efforts in the Emerging Business Opportunity area to create models that drive sustainable "growth breakthroughs." Finally, Rosemarie has spearheaded the development of several trade secret models, frameworks and to select and nurture sustainable growth opportunities; one model is for the Life Sciences industry called "Industry Leading R&D Performance"
Jonathan Lui
Jonathan Lui
Managing Director, The Center for Advancing Innovation, INC.
Jonathan has worked on a variety of portfolio strategy, operational optimization and business strategy engagements. When a problem is labeled "impossible," he's charged with solving it, which he has done with grace and poise. He has worked with the following client efforts: Novartis, Glaxo Smith Kline and several others. For example, he led an engagement to assess one large pharma's suite of clinical trials; identified ways to make them more successful and also generated financial models to illustrate the value of pursuing recommendations. Jonathan has also been the lead due diligence consultant on a portfolio strategy engagement for an infectious disease drug, device and diagnostic company, where the team identified a large exist as well as a bootstrap strategy to mitigate risk for potential investors
Managing Director, The Center for Advancing Innovation, INC.
Jonathan has worked on a variety of portfolio strategy, operational optimization and business strategy engagements. When a problem is labeled "impossible," he's charged with solving it, which he has done with grace and poise. He has worked with the following client efforts: Novartis, Glaxo Smith Kline and several others. For example, he led an engagement to assess one large pharma's suite of clinical trials; identified ways to make them more successful and also generated financial models to illustrate the value of pursuing recommendations. Jonathan has also been the lead due diligence consultant on a portfolio strategy engagement for an infectious disease drug, device and diagnostic company, where the team identified a large exist as well as a bootstrap strategy to mitigate risk for potential investors
Youhong Wang
Youhong Wang, Ph.D.
Strategy Consultant, The Center for Advancing Innovation, INC.
Youhong Wang is a strategy consultant for The Center for Advancing Innovation. Currently, she has worked on an engagement for the NIH and NCI, where she has led the assessment of 800+ inventions, and also led strategic assessments of economic burden, incidence rates, prevalence rates, market size/growth, etc. using a variety of databases and complex algorithms. She also performed “deep dives" for NCI technologies tailored to align with the strategic priority of several pharmaceutical companies, prepared deliverables, and presented to the interested parties. Prior to working with the Center, Youhong worked at the NIH and has extensive experience in bench research and protocol design
Youhong got her M.D. degree in P.R. China. She then obtained a Ph.D. in Tumor Biology from Georgetown University Lombardi Cancer Center, Washington DC, for her investigation of the PI3K signaling pathway in breast cancer. As a postdoctoral IRTA fellow at the NIH, she focused on the GPCR/ELMO pathway mechanism in chemotaxis and metastasis of cervical cancers. Youhong’s interests include traveling, cooking, reading, rock-climbing, and swimming
Strategy Consultant, The Center for Advancing Innovation, INC.
Youhong Wang is a strategy consultant for The Center for Advancing Innovation. Currently, she has worked on an engagement for the NIH and NCI, where she has led the assessment of 800+ inventions, and also led strategic assessments of economic burden, incidence rates, prevalence rates, market size/growth, etc. using a variety of databases and complex algorithms. She also performed “deep dives" for NCI technologies tailored to align with the strategic priority of several pharmaceutical companies, prepared deliverables, and presented to the interested parties. Prior to working with the Center, Youhong worked at the NIH and has extensive experience in bench research and protocol design
Youhong got her M.D. degree in P.R. China. She then obtained a Ph.D. in Tumor Biology from Georgetown University Lombardi Cancer Center, Washington DC, for her investigation of the PI3K signaling pathway in breast cancer. As a postdoctoral IRTA fellow at the NIH, she focused on the GPCR/ELMO pathway mechanism in chemotaxis and metastasis of cervical cancers. Youhong’s interests include traveling, cooking, reading, rock-climbing, and swimming
Jasmine J. Yang, Ph.D.
Jasmine J. Yang, Ph.D.
Technology Transfer Specialist, the Technology Transfer Center (TTC) at the NIH National Cancer Institute (NCI)
Jasmine Yang is a Technology Transfer Specialist at the NCI Technology Transfer Center under the Cancer Research Training Award. She is responsible for negotiating agreements such as Cooperative Research and Development Agreements (CRADAs), Collaboration Agreements, Material Transfer Agreements (MTAs) and Confidential Disclosure Agreements (CDAs) and managing a portfolio of inventions for intramural scientists at NCI. In addition, she handles marketing activities to promote R&D partnerships between NCI and external parties. This includes managing relationships with life sciences business development leads, developing marketing materials, conducting outreach and assisting in improving overall marketing strategies for NCI TTC. Prior to her position at NCI, she was an intern at the Office of Technology Development at Harvard University. She also conducted neuroendocrinology research at Massachusetts General Hospital and Brown University. Jasmine completed her Ph.D. in Biology at Boston University. During her academic career, Jasmine published articles in peer-reviewed journals and an instructional laboratory manual for undergraduate students. She also served in leadership roles in peer organizations and as a mentor for minority women in the life sciences.
Technology Transfer Specialist, the Technology Transfer Center (TTC) at the NIH National Cancer Institute (NCI)
Jasmine Yang is a Technology Transfer Specialist at the NCI Technology Transfer Center under the Cancer Research Training Award. She is responsible for negotiating agreements such as Cooperative Research and Development Agreements (CRADAs), Collaboration Agreements, Material Transfer Agreements (MTAs) and Confidential Disclosure Agreements (CDAs) and managing a portfolio of inventions for intramural scientists at NCI. In addition, she handles marketing activities to promote R&D partnerships between NCI and external parties. This includes managing relationships with life sciences business development leads, developing marketing materials, conducting outreach and assisting in improving overall marketing strategies for NCI TTC. Prior to her position at NCI, she was an intern at the Office of Technology Development at Harvard University. She also conducted neuroendocrinology research at Massachusetts General Hospital and Brown University. Jasmine completed her Ph.D. in Biology at Boston University. During her academic career, Jasmine published articles in peer-reviewed journals and an instructional laboratory manual for undergraduate students. She also served in leadership roles in peer organizations and as a mentor for minority women in the life sciences.
Melissa Maderia
Melissa Maderia, Ph.D.
Technology Transfer Specialist, the Technology Transfer Center (TTC) at the NIH National Cancer Institute (NCI)
Dr. Maderia completed her Ph.D. in Chemistry from Texas A&M University in 2000. She continued from there to the University of Minnesota for a post-doctoral fellowship in biochemistry and molecular biology and then to the National Cancer Institute for a second post-doctoral fellowship in the Laboratory of Medicinal Chemistry (now called the Chemical Biology Laboratory). Deciding to transition from the lab to a career in technology transfer, Dr. Maderia joined the Technology Transfer Center at the National Cancer Institute (NCI-TTC) in November 2005 as a fellow before joining the office in January of 2007 as a full time Technology Transfer Specialist. Dr. Maderia completed her Masters in Management with Marketing in 2011 and an MBA in 2013 from University of Maryland University College. She currently promotes technologies that are developed at the NIH to attract industry partners to further develop and commercialize the technologies to benefit public health. Her focus is in the areas of cancer, neurology, and stroke. She also works to promote resources at NIH that are available to industry (and academia), including funding, expertise, materials, technologies, pre-clinical testing and screening, as well as access to clinical sites for any projects that benefit public health.
Technology Transfer Specialist, the Technology Transfer Center (TTC) at the NIH National Cancer Institute (NCI)
Dr. Maderia completed her Ph.D. in Chemistry from Texas A&M University in 2000. She continued from there to the University of Minnesota for a post-doctoral fellowship in biochemistry and molecular biology and then to the National Cancer Institute for a second post-doctoral fellowship in the Laboratory of Medicinal Chemistry (now called the Chemical Biology Laboratory). Deciding to transition from the lab to a career in technology transfer, Dr. Maderia joined the Technology Transfer Center at the National Cancer Institute (NCI-TTC) in November 2005 as a fellow before joining the office in January of 2007 as a full time Technology Transfer Specialist. Dr. Maderia completed her Masters in Management with Marketing in 2011 and an MBA in 2013 from University of Maryland University College. She currently promotes technologies that are developed at the NIH to attract industry partners to further develop and commercialize the technologies to benefit public health. Her focus is in the areas of cancer, neurology, and stroke. She also works to promote resources at NIH that are available to industry (and academia), including funding, expertise, materials, technologies, pre-clinical testing and screening, as well as access to clinical sites for any projects that benefit public health.
Michele Newton
Michele Newton
Marketing Specialist, the Technology Transfer Center (TTC) at the NIH National Cancer Institute (NCI)
Michele Newton is a marketing specialist at the National Cancer Institute’s (NCI) Technology Transfer Center (TTC). In this position, Michele supports TTC’s marketing efforts to facilitate partnerships to accelerate the development of the NCI patent portfolio. Prior to NCI, Michele was the North America regional marketing manager for JDSU, a leading provider of optical products and test and measurement solutions for the communications industry. In that role, Michele lead the strategic planning and implementation of targeted communication programs for JDSU’s North American communications test and measurement market. In spring 2014, Michele was a faculty member and presenter at EXHIBITOR 2014, a professional conference that champions best practices in trade shows and events. Michele is also a supporting contributor to the Breast Cancer Startup Challenge team. She received her BA in Journalism and Public Relations from Indiana University of Pennsylvania.
Marketing Specialist, the Technology Transfer Center (TTC) at the NIH National Cancer Institute (NCI)
Michele Newton is a marketing specialist at the National Cancer Institute’s (NCI) Technology Transfer Center (TTC). In this position, Michele supports TTC’s marketing efforts to facilitate partnerships to accelerate the development of the NCI patent portfolio. Prior to NCI, Michele was the North America regional marketing manager for JDSU, a leading provider of optical products and test and measurement solutions for the communications industry. In that role, Michele lead the strategic planning and implementation of targeted communication programs for JDSU’s North American communications test and measurement market. In spring 2014, Michele was a faculty member and presenter at EXHIBITOR 2014, a professional conference that champions best practices in trade shows and events. Michele is also a supporting contributor to the Breast Cancer Startup Challenge team. She received her BA in Journalism and Public Relations from Indiana University of Pennsylvania.
Vio Conley, M.S.
Vio Conley, M.S.
Technology Transfer Specialist, the Technology Transfer Center (TTC) at the National Cancer Institute, NIH
Biotechnology Studies, University of Maryland University College.
Ms. Conley completed her Masters in Biotechnology Studies in 2005 and a B.S. in Business Administration in 2000 at the University of Maryland University College. She is a full time Technology Transfer Specialist at the NCI Technology Transfer Center (TTC) Competitive Service Center and primarily support technology transfer activities for the National Institute on Drug Abuse (NIDA) and the National Institute on Aging (NIA). Her responsibilities include negotiating Technology Transfer Agreements with Industry, Academia and Non-Profits for researchers at the NIDA and the NIA so that research collaborations can be conducted. Amongst those agreements she handles regularly are, Clinical Trials Agreements, Material Transfers, Confidential Disclosure Agreements, Cooperative Research and Development Agreements (CRADAS), Screening Agreements, etc. She also oversee the patent portfolio for inventors and promotes technologies that are developed at the NIH to attract industry partners for further development and commercialization to benefit public health.
Technology Transfer Specialist, the Technology Transfer Center (TTC) at the National Cancer Institute, NIH
Biotechnology Studies, University of Maryland University College.
Ms. Conley completed her Masters in Biotechnology Studies in 2005 and a B.S. in Business Administration in 2000 at the University of Maryland University College. She is a full time Technology Transfer Specialist at the NCI Technology Transfer Center (TTC) Competitive Service Center and primarily support technology transfer activities for the National Institute on Drug Abuse (NIDA) and the National Institute on Aging (NIA). Her responsibilities include negotiating Technology Transfer Agreements with Industry, Academia and Non-Profits for researchers at the NIDA and the NIA so that research collaborations can be conducted. Amongst those agreements she handles regularly are, Clinical Trials Agreements, Material Transfers, Confidential Disclosure Agreements, Cooperative Research and Development Agreements (CRADAS), Screening Agreements, etc. She also oversee the patent portfolio for inventors and promotes technologies that are developed at the NIH to attract industry partners for further development and commercialization to benefit public health.
